

Rheumatology Grand Rounds 2026

Rheumatology Grand Rounds 2026 - Challenging Cases in Glucocorticoid-Induced Osteoporosis

April 3, 2026 – 9:00 AM

Overall Activity Objectives:

- 1 Diagnose patients with rheumatic and musculoskeletal diseases with improved accuracy
- 2 Utilize rheumatologic tests, imaging, procedures and interventions (i.e., non-pharmacologic, pharmacologic and surgical) with increased skill
- 3 Manage patients with rheumatic and musculoskeletal diseases with greater skill
- 4 Avoid and minimize adverse events for rheumatologic conditions and diseases
- 5 Utilize practice algorithms designed for our specific rheumatologic practice with greater frequency
- 6 Utilize clinical instruments to assess rheumatologic disease activity and functional outcomes

Session Objectives:

- 1 Recognize that denosumab rebound effect leads to bone mineral density loss and greater risk of fracture.
- 2 Understand how management of glucocorticoid-induced osteoporosis is confounded by underlying disease and safety considerations of the available therapies.
- 3 Discuss where osteoanabolics should be considered in treating severe GIOP.
- 4 To appreciate that PTH analogs may help with fracture outcomes, particularly pelvic fractures.
- 5 Recognize that Children get glucocorticoid-induced osteoporosis and bisphosphonates are preferred therapy when treatment is needed.

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Kenneth G Saag, MD	Faculty	Consulting Fee-Angitia Bio Consulting Fee-Arthrosi Consulting Fee-Atom Bioscience Consulting Fee-Bioaxia Consulting Fee-Convergencebio Consulting Fee-

		Crystallys Consulting Fee-Kyowa Kyrin Consulting Fee-LG Pharma Consulting Fee- Neurocrine Consulting Fee-Novo Nordisk (Any division) Consulting Fee- Shanton Consulting Fee-Sobi Grant or research support-Amgen, Inc. Grant or research support-Angitia Grant or research support-ArthroSi Grant or research support-Inventis Grant or research support-LG Pharma - 03/03/2026
Ernest R Vina, MD	Activity Director	Nothing to disclose - 10/17/2025



THE UNIVERSITY OF ARIZONA

College of Medicine

Tucson